Ratings Roche Holding AG

Equities

Market Closed - Swiss Exchange Other stock markets 16:31:02 10/07/2025 BST			5-day change	1st Jan Change
263.00 ^CHF	+1.15%		+1.11%	+2.94%

07-10	ROCHE HOLDINGS AG : Buy rating from UBS	ZD
07-09	Swiss Market Index Closes Higher; SGS Shares Down	MT

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
The company is in a robust financial situation considering its net cash and margin position.

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
With an enterprise value anticipated at 3.49 times the sales for the current fiscal year, the company turns out to be overvalued.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Source: Surperformance

Source: MSCI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	ROCHE HOLDING AG				262B
	ELI LILLY AND COMPANY				706B
	JOHNSON & JOHNSON				376B
	ABBVIE INC.				337B
	NOVO NORDISK A/S				309B
	NOVARTIS AG				240B
	ASTRAZENECA PLC				218B
	MERCK & CO., INC.				210B
	AMGEN INC.				159B
	PFIZER, INC.				145B
	Average				296.3B
	Weighted average by Cap.